Detailed Instructions: Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
See one example below:
Problem: Context: Architecturally, the school has a Catholic character. Atop the Main Building's gold dome is a golden statue of the Virgin Mary. Immediately in front of the Main Building and facing it, is a copper statue of Christ with arms upraised with the legend 'Venite Ad Me Omnes'. Next to the Main Building is the Basilica of the Sacred Heart. Immediately behind the basilica is the Grotto, a Marian place of prayer and reflection. It is a replica of the grotto at Lourdes, France where the Virgin Mary reputedly appeared to Saint Bernadette Soubirous in 1858. At the end of the main drive (and in a direct line that connects through 3 statues and the Gold Dome), is a simple, modern stone statue of Mary.
Question: To whom did the Virgin Mary allegedly appear in 1858 in Lourdes France?
Solution: Saint Bernadette Soubirous
Explanation: This is the correct answer. Because the question is asking for the name of the person and following sentence from the passage answers it: It is a replica of the grotto at Lourdes, France where the Virgin Mary reputedly appeared to Saint Bernadette Soubirous in 1858.

Problem: Context: We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients with relapsed/refractory multiple myeloma in a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression, B was discontinued and high-dose dexamethasone could be added to S/plc. Response and progression-free survival (PFS) were analyzed pre-dexamethasone by European Group for Blood and Marrow Transplantation (EBMT) criteria. For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103). Sustained suppression of C-reactive protein, a marker reflective of inhibition of interleukin-6 activity, was seen with S + B. Siltuximab did not affect B pharmacokinetics. Siltuximab/placebo discontinuation (75 versus 66%), grade 3 neutropenia (49 versus 29%), thrombocytopenia (48 versus 34%), and all-grade infections (62 versus 49%) occurred more frequently with S + B. The addition of siltuximab to bortezomib did not appear to improve PFS or OS despite a numerical increase in response rate in patients with relapsed or refractory multiple myeloma.
Question: Which interleukin is blocked by Siltuximab?
Solution:
interleukin-6